MPO and breast cancer: In the multiple biomarker study (TnI, CRP, GDF-15, MPO, PlGF, and sFlt-1) by Ky et al., only early increases in TnI and MPO levels were associated with subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.